Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03031730 · ADVERSE EVENTS

Adverse events

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma · Source last updated 2026-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
At least 6 months of treatment, an average of 1 year
Other-event reporting threshold
0%

No patients were enrolled under Part A (Dose-escalation) 120, 190 and 240 mg.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Part A (Dose-escalation) 60 mg

Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)

2 / 66 / 60 / 6
Part A (Dose-escalation) 90 mg

Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)

7 / 1010 / 101 / 10
Part A (Dose-escalation) 120 mg

Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)

0 / 00 / 00 / 0
Part A (Dose-escalation) 190 mg

Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)

0 / 00 / 00 / 0
Part A (Dose-escalation) 240 mg

Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)

0 / 00 / 00 / 0

Group identifiers: EG000: Part A (Dose-escalation) 60 mg · EG001: Part A (Dose-escalation) 90 mg · EG002: Part A (Dose-escalation) 120 mg · EG003: Part A (Dose-escalation) 190 mg · EG004: Part A (Dose-escalation) 240 mg

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Eye disorders - Other, specify - Vision Decreased
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Eye pain
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Infections & infestations - Other - Covid-19 Infection
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Platelet count decreased
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Pancreatitis
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Nervous system disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Stroke
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Lung infection
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Urinary tract infection
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    White blood cell decreased
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Vascular disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Thromboembolic event
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Diarrhea

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    White blood cell decreased
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Lymphocyte count decreased
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Platelet count decreased
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Anemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Diarrhea
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hyperglycemia
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Neutrophil count decreased
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Fatigue
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Nausea
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hypokalemia
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hyponatremia
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hypophosphatemia
Complete source fields
description
No patients were enrolled under Part A (Dose-escalation) 120, 190 and 240 mg.
event Groups
  1. deaths Num Affected
    0
    deaths Num At Risk
    6
    description
    Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)
    id
    EG000
    other Num Affected
    6
    other Num At Risk
    6
    serious Num Affected
    2
    serious Num At Risk
    6
    title
    Part A (Dose-escalation) 60 mg
  2. deaths Num Affected
    1
    deaths Num At Risk
    10
    description
    Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)
    id
    EG001
    other Num Affected
    10
    other Num At Risk
    10
    serious Num Affected
    7
    serious Num At Risk
    10
    title
    Part A (Dose-escalation) 90 mg
  3. deaths Num Affected
    0
    deaths Num At Risk
    0
    description
    Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)
    id
    EG002
    other Num Affected
    0
    other Num At Risk
    0
    serious Num Affected
    0
    serious Num At Risk
    0
    title
    Part A (Dose-escalation) 120 mg
  4. deaths Num Affected
    0
    deaths Num At Risk
    0
    description
    Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)
    id
    EG003
    other Num Affected
    0
    other Num At Risk
    0
    serious Num Affected
    0
    serious Num At Risk
    0
    title
    Part A (Dose-escalation) 190 mg
  5. deaths Num Affected
    0
    deaths Num At Risk
    0
    description
    Escalating doses of KRT-232 (DL1 60 mg, DL2 90 mg, DL3 120 mg, DL4 190 mg, DL5 240 mg) in combination with Carfilzomib, Lenalidomide, Dexamethasone (KRd)
    id
    EG004
    other Num Affected
    0
    other Num At Risk
    0
    serious Num Affected
    0
    serious Num At Risk
    0
    title
    Part A (Dose-escalation) 240 mg
frequency Threshold
0
other Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    White blood cell decreased
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Lymphocyte count decreased
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Platelet count decreased
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Anemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      3
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Diarrhea
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      5
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hyperglycemia
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Investigations
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Neutrophil count decreased
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    General disorders
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Fatigue
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      6
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Nausea
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hypokalemia
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hyponatremia
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Metabolism and nutrition disorders
    stats
    1. group Id
      EG000
      num Affected
      4
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Hypophosphatemia
serious Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Eye disorders - Other, specify - Vision Decreased
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Eye pain
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Infections & infestations - Other - Covid-19 Infection
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    Platelet count decreased
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Pancreatitis
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Nervous system disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Stroke
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Lung infection
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Infections and infestations
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Urinary tract infection
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      10
    3. group Id
      EG002
      num At Risk
      0
    4. group Id
      EG003
      num At Risk
      0
    5. group Id
      EG004
      num At Risk
      0
    term
    White blood cell decreased
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Vascular disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Thromboembolic event
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      6
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      10
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      0
    4. group Id
      EG003
      num Affected
      0
      num At Risk
      0
    5. group Id
      EG004
      num Affected
      0
      num At Risk
      0
    term
    Diarrhea
time Frame
At least 6 months of treatment, an average of 1 year

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice